Literature DB >> 30444720

Peroxisome proliferator-activated receptor gamma and BRCA1.

Priscilla A Furth1.   

Abstract

Peroxisome proliferator-activated receptor gamma agonists have been proposed as breast cancer preventives. Individuals who carry a mutated copy of BRCA1, DNA repair-associated gene, are at increased risk for development of breast cancer. Published data in the field suggest there could be interactions between peroxisome proliferator-activated receptor gamma and BRCA1 that could influence the activity of peroxisome proliferator-activated receptor gamma agonists for prevention. This review explores these possible interactions between peroxisome proliferator-activated receptor gamma, peroxisome proliferator-activated receptor gamma agonists and BRCA1 and discusses feasible experimental directions to provide more definitive information on the potential connections.

Entities:  

Keywords:  BRCA1; PPARG agonist; breast cancer prevention; peroxisome proliferator-activated receptor gamma

Mesh：

Substances：

Year:  2019        PMID： 30444720      PMCID： PMC6494719          DOI： 10.1530/ERC-18-0449

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  56 in total

1.  Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.

Authors:  Lisa D Yee; Nita Williams; Ping Wen; Donn C Young; Joanne Lester; Maria V Johnson; William B Farrar; Michael J Walker; Stephen P Povoski; Saul Suster; Charis Eng
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

Review 2.  The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.

Authors:  Giuseppe Derosa; Amirhossein Sahebkar; Pamela Maffioli
Journal:  J Cell Physiol       Date:  2017-03-27       Impact factor: 6.384

Review 3.  Hereditary Ovarian Cancer and Risk Reduction.

Authors:  Lesley Andrews; David G Mutch
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2017-01-17       Impact factor: 5.237

4.  Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.

Authors:  Miguel Pignatelli; Claudia Cocca; Angel Santos; Ana Perez-Castillo
Journal:  Oncogene       Date:  2003-08-21       Impact factor: 9.867

5.  Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma.

Authors:  Maddalena T Tilli; M Silvina Frech; Mary E Steed; Kathleen S Hruska; Michael D Johnson; Jodi A Flaws; Priscilla A Furth
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Stromal adipocyte PPARγ protects against breast tumorigenesis.

Authors:  Graham Skelhorne-Gross; Alexis L Reid; Anthony J Apostoli; Michael A Di Lena; Rachel E Rubino; Nichole T Peterson; Mark Schneider; Sandip K SenGupta; Frank J Gonzalez; Christopher J B Nicol
Journal:  Carcinogenesis       Date:  2012-05-11       Impact factor: 4.944

7.  A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Authors:  Michael J Pishvaian; John L Marshall; Andrew J Wagner; Jimmy J Hwang; Shakun Malik; Ion Cotarla; John F Deeken; A Ruth He; Hirut Daniel; Abdel-Baset Halim; Hamim Zahir; Catherine Copigneaux; Kejian Liu; Robert A Beckman; George D Demetri
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

8.  Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.

Authors:  Alexandra Rogue; Catherine Spire; Manuel Brun; Nancy Claude; André Guillouzo
Journal:  PPAR Res       Date:  2010-10-19       Impact factor: 4.964

9.  Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Authors:  Yoshito Komatsu; Takayuki Yoshino; Kentaro Yamazaki; Satoshi Yuki; Nozomu Machida; Takahide Sasaki; Ichinosuke Hyodo; Yutaka Yachi; Hiroshi Onuma; Atsushi Ohtsu
Journal:  Invest New Drugs       Date:  2013-12-15       Impact factor: 3.850

10.  RANKL/RANK control Brca1 mutation- .

Authors:  Verena Sigl; Kwadwo Owusu-Boaitey; Purna A Joshi; Anoop Kavirayani; Gerald Wirnsberger; Maria Novatchkova; Ivona Kozieradzki; Daniel Schramek; Nnamdi Edokobi; Jerome Hersl; Aishia Sampson; Ashley Odai-Afotey; Conxi Lazaro; Eva Gonzalez-Suarez; Miguel A Pujana; For Cimba; Holger Heyn; Enrique Vidal; Jennifer Cruickshank; Hal Berman; Renu Sarao; Melita Ticevic; Iris Uribesalgo; Luigi Tortola; Shuan Rao; Yen Tan; Georg Pfeiler; Eva Yhp Lee; Zsuzsanna Bago-Horvath; Lukas Kenner; Helmuth Popper; Christian Singer; Rama Khokha; Laundette P Jones; Josef M Penninger
Journal:  Cell Res       Date:  2016-05-31       Impact factor: 25.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.